Mesoblast (MESO) Revenue & Revenue Breakdown
Mesoblast Revenue Highlights
Latest Revenue (Y)
$7.50M
Latest Revenue (Q)
$1.69M
Main Geography (Y)
AUSTRALIA
Mesoblast Revenue by Period
Mesoblast Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-06-30 | $7.50M | -26.54% |
| 2022-06-30 | $10.21M | 36.95% |
| 2021-06-30 | $7.46M | -76.81% |
| 2020-06-30 | $32.16M | 92.30% |
| 2019-06-30 | $16.72M | -3.57% |
| 2018-06-30 | $17.34M | 618.95% |
| 2017-06-30 | $2.41M | -94.33% |
| 2016-06-30 | $42.55M | 79.16% |
| 2015-06-30 | $23.75M | -8.59% |
| 2014-06-30 | $25.98M | -9.75% |
| 2013-06-30 | $28.79M | -24.80% |
| 2012-06-30 | $38.28M | -68.34% |
| 2011-06-30 | $120.92M | 2198468.82% |
| 2010-06-30 | $5.50K | -99.38% |
| 2009-06-30 | $890.71K | -2.10% |
| 2008-06-30 | $909.81K | -45.82% |
| 2007-06-30 | $1.68M | -40.49% |
| 2006-06-30 | $2.82M | 461.11% |
| 2005-06-30 | $502.88K | - |
Mesoblast generated $7.50M in revenue during NA 2023, up -26.54% compared to the previous quarter, and up 43.26% compared to the same period a year ago.
Mesoblast Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.69M | - |
| 2023-09-30 | $1.69M | -20.80% |
| 2023-06-30 | $2.14M | 10.31% |
| 2023-03-31 | $1.94M | -2.07% |
| 2022-12-31 | $1.98M | 37.21% |
| 2022-09-30 | $1.44M | -35.12% |
| 2022-06-30 | $2.22M | 10.59% |
| 2022-03-31 | $2.01M | -15.58% |
| 2021-12-31 | $2.38M | -33.72% |
| 2021-09-30 | $3.59M | 80.06% |
| 2021-06-30 | $2.00M | 4.34% |
| 2021-03-31 | $1.91M | -14.45% |
| 2020-12-31 | $2.24M | 73.47% |
| 2020-09-30 | $1.29M | 86.27% |
| 2020-06-30 | $692.00K | -94.27% |
| 2020-03-31 | $12.08M | 513.56% |
| 2019-12-31 | $1.97M | -88.33% |
| 2019-09-30 | $16.87M | 757.75% |
| 2019-06-30 | $1.97M | 57.49% |
| 2019-03-31 | $1.25M | -33.21% |
| 2018-12-31 | $1.87M | -83.93% |
| 2018-09-30 | $11.64M | 584.53% |
| 2018-06-30 | $1.70M | 71.54% |
| 2018-03-31 | $991.00K | -92.54% |
| 2017-12-31 | $13.28M | 1031.43% |
| 2017-09-30 | $1.17M | 107.42% |
| 2017-06-30 | $566.00K | -37.18% |
| 2017-03-31 | $901.00K | 63.82% |
| 2016-12-31 | $550.00K | 39.24% |
| 2016-09-30 | $395.00K | -98.53% |
| 2016-06-30 | $26.88M | 548.94% |
| 2016-03-31 | $4.14M | 3.19% |
| 2015-12-31 | $4.01M | -46.57% |
| 2015-09-30 | $7.51M | -7.96% |
| 2015-06-30 | $8.16M | 86.50% |
| 2014-12-31 | $4.38M | - |
Mesoblast generated $1.69M in revenue during Q2 2024, up 0.00% compared to the previous quarter, and up 117.39% compared to the same period a year ago.
Mesoblast Revenue Breakdown
Mesoblast Revenue Breakdown by Country
Annual Revenue by Country
| Country | Jun 20 |
|---|---|
| AUSTRALIA | $20.00M |
Latest
Mesoblast's latest annual revenue breakdown by geography, as of Jun 20: AUSTRALIA (100.00%).
Mesoblast Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FBIO | Fortress Biotech | $59.66M | $14.63M |
| ETON | Eton Pharmaceuticals | $31.64M | $10.32M |
| FENC | Fennec Pharmaceuticals | $21.64M | $6.97M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| MESO | Mesoblast | $7.50M | $1.69M |
| VRCA | Verrica Pharmaceuticals | $5.12M | $-1.86M |
| FIXX | Q32 Bio | $1.16M | - |
| ADTX | Aditxt | $645.18K | $6.85K |
| LPCN | Lipocine | $109.99K | $89.56K |
| APTO | Aptose Biosciences | - | - |
| LIAN | LianBio | - | - |
| XFOR | X4 Pharmaceuticals | - | $560.00K |
| MBIO | Mustang Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| CNTB | Connect Biopharma | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| ACHL | Achilles Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| VIRI | Virios Therapeutics | - | - |
| NUVB | Nuvation Bio | - | $727.00K |
| ELDN | Eledon Pharmaceuticals | - | - |